Arielle Crespel1,2, Philippe Gelisse1,2, Ngoc Phuong Loc Tang1, Pierre Genton3. 1. Epilepsy Unit, Hôpital Gui de Chauliac, Montpellier, France. 2. Research Unit (URCMA: Unité de Recherche sur les Comportements et Mouvements Anormaux), INSERM, U661, Montpellier, France. 3. Centre Saint Paul-H. Gastaut, Marseille, France.
Abstract
OBJECTIVE: Perampanel (PER) was used in 12 patients with Unverricht-Lundborg disease (ULD) to evaluate its efficacy against myoclonus and seizures. METHODS: We treated 11 patients with EPM1 mutations (6 F, 5 M, aged 13-62 years) and a 43-year-old man with de novo KCNC1 mutation. PER was introduced by 2 mg steps at 2-4 week intervals until 6 mg/day, with a possible dose reduction or dose increase. RESULTS: Ten patients had a clear clinical response of myoclonus, and five were able to reduce concomitant therapy. Improvement was noted sometimes as soon as with 2 mg/day. Epileptic seizures stopped on PER in the six patients who still had experienced generalized tonic-clonic or myoclonic seizures (100%). Some abatement of efficacy on myoclonus was seen in two patients who still retained some benefit. Weight gain was reported in six patients (50%). Psychological and behavioral side-effects were observed in six patients (50%) and led to withdrawal of PER in three cases and dose reduction in three, with abatement of the problems. SIGNIFICANCE: This study provides evidence that for ULD patients, PER may show marked efficacy even in severe cases, particularly against myoclonus, but also against seizures. PER should thus be tried in ULD patients whose seizures are not satisfactorily controlled. Its use is limited because of psychological and behavioral side effects, with higher doses of approximately 6 mg/day or greater likely risk factors. Wiley Periodicals, Inc.
OBJECTIVE:Perampanel (PER) was used in 12 patients with Unverricht-Lundborg disease (ULD) to evaluate its efficacy against myoclonus and seizures. METHODS: We treated 11 patients with EPM1 mutations (6 F, 5 M, aged 13-62 years) and a 43-year-old man with de novo KCNC1 mutation. PER was introduced by 2 mg steps at 2-4 week intervals until 6 mg/day, with a possible dose reduction or dose increase. RESULTS: Ten patients had a clear clinical response of myoclonus, and five were able to reduce concomitant therapy. Improvement was noted sometimes as soon as with 2 mg/day. Epileptic seizures stopped on PER in the six patients who still had experienced generalized tonic-clonic or myoclonic seizures (100%). Some abatement of efficacy on myoclonus was seen in two patients who still retained some benefit. Weight gain was reported in six patients (50%). Psychological and behavioral side-effects were observed in six patients (50%) and led to withdrawal of PER in three cases and dose reduction in three, with abatement of the problems. SIGNIFICANCE: This study provides evidence that for ULDpatients, PER may show marked efficacy even in severe cases, particularly against myoclonus, but also against seizures. PER should thus be tried in ULDpatients whose seizures are not satisfactorily controlled. Its use is limited because of psychological and behavioral side effects, with higher doses of approximately 6 mg/day or greater likely risk factors. Wiley Periodicals, Inc.
Authors: Edoardo Ferlazzo; Dorothee Kasteleijn-Nolst Trenite; Gerrit-Jan de Haan; Felix Felix Nitschke; Saija Ahonen; Sara Gasparini; Berge A Minassian Journal: Curr Pharm Des Date: 2017 Impact factor: 3.116
Authors: Giovanni Assenza; Cristofaro Nocerino; Mario Tombini; Giancarlo Di Gennaro; Alfredo D'Aniello; Alberto Verrotti; Alfonso Marrelli; Lorenzo Ricci; Jacopo Lanzone; Vincenzo Di Lazzaro; Leonilda Bilo; Antonietta Coppola Journal: Front Neurol Date: 2021-03-24 Impact factor: 4.003
Authors: Tobias Baumgartner; Mar Carreño; Rodrigo Rocamora; Francesca Bisulli; Antonella Boni; Milan Brázdil; Ondrej Horak; Dana Craiu; Cristina Pereira; Renzo Guerrini; Victoria San Antonio-Arce; Andreas Schulze-Bonhage; Sameer M Zuberi; Tove Hallböök; Reetta Kalviainen; Lieven Lagae; Sylvie Nguyen; Sofia Quintas; Ana Franco; J Helen Cross; Matthew Walker; Alexis Arzimanoglou; Sylvain Rheims; Tiziana Granata; Laura Canafoglia; Cecilie Johannessen Landmark; Arjune Sen; Rohini Rattihalli; Rima Nabbout; Elena Tartara; Manuela Santos; Rui Rangel; Pavel Krsek; Petr Marusic; Nicola Specchio; Kees P J Braun; Patricia Smeyers; Vicente Villanueva; Katarzyna Kotulska; Rainer Surges Journal: Epilepsia Open Date: 2021-01-13